Desvenlafaxine for Painful Diabetic Peripheral Neuropathy?
the MPR take:
Desvenlafaxine is the active ingredient in two FDA-approved drugs indicated for the treatment of major depressive disorder (Khedezla, Pristiq), but a new study published in the Journal of Pain Research explores whether this serotonin-norepinephrine reuptake inhibitor may be helpful in treating pain associated with diabetic peripheral neuropathy (DPN). The 13-week trial included 412 patients with painful DPN who were randomized to receive either desvenlafaxine 50, 100, 200, or 400mg/day or placebo. After 6 weeks of treatment the 50mg and 400mg doses were stopped. Primary endpoint for the study was change from baseline in pain intensity numeric rating scale (NRS) score. Study results at week 13 included:
- Mean change in NRS score was significantly greater for patients in the desvenlafaxine 200mg and 400mg groups compared with placebo.
- For the 50mg and 100mg groups, NRS score differences were not statistically significant from placebo.
- Nausea and dizziness were the most common ADRs.
Researchers concluded that desvenlafaxine at 200mg and 400mg/day was effective in treating pain associated with diabetic peripheral neuropathy and was well-tolerated in the study. Activity impairment improved at all doses as well.
Purpose: To assess the safety and efficacy of the serotonin–norepinephrine reuptake inhibitor desvenlafaxine in adults with painful diabetic peripheral neuropathy (DPN). Patients and methods: This was a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study of desvenlafaxine in adults with painful DPN.